AI English summary of an SEC filing — figures as filed

Edwards Lifesciences said Scott Ullem, its Chief Financial Officer, informed the company of his decision to transition from his role by mid-year 2026 on October 30, 2025.

8-KDeparture or Appointment of Directors or Certain OfficersFiled Oct 30, 2025Period of report Oct 30, 2025Summary published (UTC) Oct 12, 2026

Key points

AI summary

Edwards Lifesciences said Scott Ullem, its Chief Financial Officer, informed the company of his decision to transition from his role by mid-year 2026 on October 30, 2025.
The company said it is initiating a selection process to appoint a new Chief Financial Officer. The press release said this planned transition will enable continuity and a smooth transfer of responsibilities.
Edwards Lifesciences said in the press release that following the appointment of a new Chief Financial Officer, Ullem will continue in an advisory role.
The company said it issued a press release on October 30, 2025 announcing a CFO transition plan and filed it as Exhibit 99.1 under Item 7.01 Regulation FD Disclosure. It said the transition timing and continuity goals are forward-looking statements.

Summary

AI-written

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

Chief Financial Officer Scott Ullem Decides to Transition From Role by Mid-Year 2026

Edwards Lifesciences said Scott Ullem, its Chief Financial Officer, informed the company of his decision to transition from his role by mid-year 2026 on October 30, 2025.

Source · Based on the filing body and exhibits

Selection Process Initiated for New Chief Financial Officer

The company said it is initiating a selection process to appoint a new Chief Financial Officer. The press release said this planned transition will enable continuity and a smooth transfer of responsibilities.

Source · Based on the filing body and exhibits

Ullem to Serve in Advisory Role Following Successor's Appointment

Edwards Lifesciences said in the press release that following the appointment of a new Chief Financial Officer, Ullem will continue in an advisory role.

Source · Based on the filing body and exhibits

Press Release Filed as Regulation FD Disclosure; Transition Statements Are Forward-Looking

The company said it issued a press release on October 30, 2025 announcing a CFO transition plan and filed it as Exhibit 99.1 under Item 7.01 Regulation FD Disclosure. It said the transition timing and continuity goals are forward-looking statements.

Source · Based on the filing body and exhibits

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

View the original filing on SEC EDGAR ↗

Unauthorized scraping, data storage and database creation prohibited

Without prior written consent, you must not crawl or scrape data compiled and organized by Chickstock or its analysis and summaries, or collect them repeatedly or in bulk for storage, ingestion or database creation. Repurposing, redistribution, sale and use to build other services are also prohibited.

Unauthorized use may result in access restrictions, demands to stop infringement and delete copies, and claims for damages. Violations of applicable law may also give rise to criminal liability.

Uses permitted by law, the Terms of Service or a separate agreement remain subject to their respective scope. Rights in individual source materials, including original filings, remain with their respective rights holders.